{"doi":"10.1093/ageing/afab167","title":"Aducanumab and the certainty of evidence","abstract":"The decision to approve the monoclonal antibody aducanumab as a treatment for dementia has sparked considerable controversy.• The trial evidence for clinical efficacy is highly uncertain with conflicting results of trials and small effect sizes.• The approval was based on aducanumab's ability to reduce amyloid burden, however whether this translates into clinical benefit is also highly uncertain.","journal":"Age and Ageing","year":2021,"id":184080,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9531,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":3134,"name":"Terence J. Quinn","orcid":"0000-0003-1401-0181","position":1,"is_corresponding":false},{"id":643446,"name":"Jenny McCleery","orcid":null,"position":0,"is_corresponding":true}],"reference_count":5,"raw_metadata":null,"created_at":"2026-07-18T23:48:26.340498Z","pmid":"34405228","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}